Next 10 |
2024-04-24 18:28:32 ET Summary The Inflation Reduction Act has reduced the exclusivity period for small-molecule drugs, potentially leading to earlier market entry for generic drugs. The shortened exclusivity period may create a bullish catalyst for certain stocks in the generic p...
2024-04-24 14:06:00 ET Gilead Sciences ( NASDAQ: GILD ) is scheduled to announce Q1 earnings results on Thursday, April 25th, after market close.... Read the full article on Seeking Alpha For further details see: Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidanc...
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...
2024-04-23 09:00:03 ET Summary GILD stock has given up most of its late-2022 gains due to sector-wide underperformance and disappointing data from the EVOKE-01 Phase 3 trial. Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Hence, and considering my last art...
2024-04-22 15:04:08 ET Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. ...
2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53. Positive data ...
2024-04-22 13:04:43 ET Summary Heightened geopolitical risk has caught investors flat-footed over the past week. A historical analogy is presented of the Cuban Missile Crisis, a time of even greater geopolitical risk. In the short term, selling pressure in the market is likely...
2024-04-22 12:03:00 ET Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom. The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared...
2024-04-21 08:00:00 ET As the market gears up for another eventful earnings week, investors are eagerly anticipating reports from a wide array of companies across various sectors. Big names like Tesla ( NASDAQ: TSLA ), Microsoft ( NASDAQ: MSFT ), Alphabet ( NASDAQ: GOOG ...
News, Short Squeeze, Breakout and More Instantly...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...